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ALI = acute lung injury; AQP = aquaporin; ARDS = acute respiratory distress syndrome; FiO2 = fractional inspired concentration of oxygen; IL = inter-
leukin; PaO2 = partial pressure of oxygen; TNF-α = tumor necrosis factor alpha.
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Introduction
Acute lung injury (ALI) and acute respiratory distress
syndrome (ARDS) are important because of the continued
high mortality and costs of care of these conditions. Beta
adrenergic agonists are inexpensive and are actually often
used in the treatment of patients who have ALI or ARDS for
reasons not related to attempts to improve resolution of lung
injury. For example, inhaled beta-2 adrenergic agonists are
used to decrease airway resistance when it is increased in
ALI and ARDS. Intravenously infused beta adrenergic
agonists are used when the circulation requires inotropic
support because of shock or ventricular dysfunction, both of
which are common in ALI and ARDS. It is unknown whether
beta adrenergic agonists used for these other reasons also
improve the resolution of ALI.
We have chosen to focus on the evidence that beta-2
adrenergic agonists act through three mechanisms (increased
clearance of salt and water from alveoli, anti-inflammatory
effects, and bronchodilation) to improve the pathophysiology,
and possibly the rate and success of resolution, of pulmonary
edema and ALI. This leads to the hypothesis that beta-2
adrenergic agonists may be beneficial therapy for patients
with ALI or with ARDS.
Definitions
Different definitions and scoring systems have been
developed since the “adult respiratory distress syndrome”
was first described by Ashbaugh and colleagues in 12
patients in 1967 [1]. The most current consensus conference
definition of ALI is acute onset of acute respiratory failure
characterized by PaO2/FiO2 ≤300 mmHg, bilateral infiltrates,
and pulmonary capillary wedge pressure ≤18 mmHg, or by no
clinical evidence of left atrial hypertension The definition of
ARDS differs only in that the oxygenation criterion is more
severe: PaO2/FiO2 ≤200 mmHg [2].
Review
Science review: Mechanisms of beta-receptor stimulation-
induced improvement of acute lung injury and pulmonary edema
Horacio E Groshaus, Sanjay Manocha, Keith R Walley and James A Russell
Critical Care Research Laboratories, St Paul’s Hospital and University of British Columbia, Vancouver, British Columbia, Canada
Corresponding author: James A Russell, jrussell@mrl.ubc.ca
Published online: 25 May 2004 Critical Care 2004, 8:234-242 (DOI 10.1186/cc2875)
This article is online at http://ccforum.com/content/8/4/234
© 2004 BioMed Central Ltd
Abstract
Acute lung injury (ALI) and the acute respiratory distress syndrome are complex syndromes because
both inflammatory and coagulation cascades cause lung injury. Transport of salt and water, repair and
remodeling of the lung, apoptosis, and necrosis are additional important mechanisms of injury. Alveolar
edema is cleared by active transport of salt and water from the alveoli into the lung interstitium by
complex cellular mechanisms. Beta-2 agonists act on the cellular mechanisms of pulmonary edema
clearance as well as other pathways relevant to repair in ALI. Numerous studies suggest that the
beneficial effects of beta-2 agonists in ALI include at least enhanced fluid clearance from the alveolar
space, anti-inflammatory actions, and bronchodilation. The purposes of the present review are to
consider the effects of beta agonists on three mechanisms of improvement of lung injury: edema
clearance, anti-inflammatory effects, and bronchodilation. This update reviews specifically the evidence
on the effects of beta-2 agonists in human ALI and in models of ALI. The available evidence suggests
that beta-2 agonists may be efficacious therapy in ALI. Further randomized controlled trials of beta
agonists in pulmonary edema and in acute lung injury are necessary.
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Current therapeutic strategies
The mortality of ALI has decreased over the past 20 years to
30–35%. This reduction is due to advances in ventilation, in
management of sepsis, and in general support. Only recently
has class-one evidence (adequately powered, randomized
controlled trials) become available to guide management of
patients with ALI/ARDS. A National Heart, Lung, and Blood
Institute-supported, ARDS network, randomized controlled
trial demonstrated that ventilation using low tidal volumes
(6 ml/kg lean body weight) and a limited plateau pressure
(<30 cmH2O) reduced the mortality of ARDS from 40% to
31% [3]. This has changed the ventilator management of
these patients. Ongoing investigation of the mechanisms of
lung stretch-induced injury may contribute to further
improvement of outcomes [3].
Improved management of sepsis, which is the commonest
predisposing condition that initiates ALI and ARDS, is also
supported by class-one evidence. The PROWESS Trial
demonstrated that a 96-hour infusion of activated protein C in
patients with severe sepsis reduces mortality from 31% to
26% [4]. Recent positive randomized controlled trials are
thus leading to improved management of ALI and ARDS.
Pathophysiology of ALI relevant to beta agonists
The pathophysiology of ARDS occurs in three phases: the
initial exudative phase (up to 6 days after the initial event), the
second proliferative phase (4–10 days after the initial injury),
and a third fibrotic phase (the second and third weeks after the
initial lung injury) [5]. After the acute phase of ALI, resolution
can be rapid with complete recovery or complete resolution, or
the ALI can evolve into fibrosis. Key features of the patho-
physiology of ALI are inflammation, impaired fluid clearance,
increased airway resistance, and surfactant dysfunction.
ALI/ARDS evolves from an initial trigger of inflammation [6].
The trigger of inflammatory pathways may be infection in the
lung or infection elsewhere that initiates a systemic inflam-
matory response. Alternatively, a systemic inflammatory
response may be triggered by trauma, by pancreatitis, by
ischemia reperfusion injury, by burns, and by surgery. Once a
systemic inflammatory response is triggered, circulating
monocytes and alveolar macrophages secrete cytokines
including tumor necrosis factor alpha (TNF-α), IL-1, IL-6, and
IL-8. These pro-inflammatory cytokines activate leukocytes
and endothelial cells so that these cells increase expression
of surface adhesion molecules. Neutrophils, other leukocytes,
and platelets adhere via cognate receptors to the pulmonary
endothelium. Production of IL-8 and other chemokines within
the lung leads to recruitment of neutrophils and of other
leukocytes into the interstitial and alveolar spaces of the lung.
Activated neutrophils release proteases, leukotrienes,
reactive oxygen intermediates, and other inflammatory
molecules that amplify the inflammatory response. Reactive
oxygen intermediates and proteases directly damage alveolar–
capillary membrane integrity.
This pro-inflammatory cascade is regulated by anti-inflam-
matory mediators such as IL-10, IL-1 receptor antagonist, and
soluble TNF receptors [7,8]. Propagation of ALI can also lead
to microthrombosis and impaired fibrinolysis of the micro-
vasculature of the acutely injured lung. All of these pathways
can lead to further release of mediators into the systemic
circulation so that the systemic inflammatory response is
amplified and leads to dysfunction of remote organ systems.
This inflammatory response in the lung in ALI decreases the
capacity of the epithelium to remove edema fluid from the
distal airspaces of the lung. Disruption of the integrity of the
alveolar–capillary membrane results in increased permea-
bility, and as a result the air spaces are flooded with protein-
rich edema fluid. Histologically, the development of pulmo-
nary edema is related to injury of the alveolar–capillary barrier.
The alveolar–capillary barrier is comprised of capillary endo-
thelium and of alveolar epithelium. The alveolar epithelium is
composed of type I cells (90–95%) and of type II cells
(5–10%). Type II cells are more resistant to initial injury. Injury
to the alveolar type I epithelial cells leads to increased
permeability, to impairment of fluid and salt transport, and to
disorganized epithelial repair. In addition to edemagenesis,
impaired alveolar–capillary barrier function may increase
permeability to bacteria and bacterial products.
After the initial injury, alveolar edema can be cleared by active
transport of salt and water into the lung interstitium through a
number of cellular mechanisms. Active transport of sodium,
and perhaps chloride, from the air spaces to the lung
interstitium is a primary mechanism driving clearance of
alveolar fluid. Water passively follows this sodium gradient.
Injury of the alveolar epithelium also reduces the production and
turnover of surfactant by type II cells, which further exacerbates
the lung injury. Surfactant is a complex of lipids and proteins that
reduces alveolar surface tension, has antibacterial properties,
and prevents pulmonary edema formation.
Mechanisms of clearance of edema from the
lung
Sodium transport through the alveolar epithelium plays a
major and active role in the clearance of alveolar fluid in both
normal and pathological conditions. The mechanisms of
sodium transport include participation of amiloride-sensitive
sodium channels on the apical membrane of alveolar type II
cells, followed by the extrusion of sodium from the basolateral
surface by the Na,K-ATPase pump. Alveolar type I cells may
also have an important role in sodium transport through the
alveolar epithelium, which is important because type I cells
comprise more than 90% of alveolar surface area.
Johnson and colleagues [9] discovered that there is expression
of three amiloride-sensitive epithelial sodium channel subunits
(α, β and γ) and two subunits (α and β) of the Na,K-ATPase in
type I cultured cells isolated from adult rat lungs. Ridge and236
Critical Care    August 2004 Vol 8 No 4 Groshaus et al.
colleagues [10] found that alveolar type I cells express both the
α1 and α2 Na,K-ATPase isoforms. Of note, the α2 isoform
plays a major role in active sodium transport. Borok and
colleagues [11] found α1 and β1 Na,K-ATPase subunits in
cultured type I cells using antibodies specific to type I and type
II alveolar cells. These observations emphasize the importance
of alveolar type I cells in sodium transport.
Sodium transport can be upregulated by both catecholamine-
dependent mechanisms and catecholamine-independent
mechanisms. For example, endogenous epinephrine release
during sepsis and ALI increases the rate of edema clearance
from alveolae [12]. Catecholamine-independent mechanisms
include corticosteroids, thyroid hormone, insulin, and several
growth factors [7,13–16].
Chloride is also an important ion that follows the electro-
chemical gradient using the cystic fibrosis transmembrane
conductance regulator [17]. Reddy and colleagues [18] and
Jiang and colleagues [19] reported that the enhancement of
sodium transport mediated by beta agonist-induced
stimulation of cAMP also increases chloride conductance.
Furthermore, O’Grady and colleagues suggested that apical
membrane chloride channel activation responds to adrenergic
agonists to cause transepithelial sodium absorption [20,21].
The transepithelial sodium absorption requires amiloride-
sensitive sodium channels.
Water follows the osmotic gradient passively and is absorbed
through water channels called aquaporins (AQPs) [7,16,22].
AQP channels are distributed along bronchopulmonary
tissues, although they are not essential to achieve a maximal
epithelial fluid transport [23]. AQP1 is expressed in
microvascular endothelium, while AQP3 and AQP4 are
expressed in large airways. AQP4 is also present in small
airways. AQP5 is present in type I alveolar cells and in
submucosal gland acinar cells. The principal functional AQP
water channels are AQP1 and AQP5. Deletion of AQP5 in
submucosal glands in the upper airways is the only AQP
deletion that reduces the fluid transport.
Injury to the epithelial alveolar barrier disrupts the integrity of
mechanisms of sodium, chloride, and water clearance
because ion transport pathways are downregulated, thus
reducing edema clearance. Hypoxia, a common feature of
ALI/ARDS, may in addition contribute to impaired edema
clearance because hypoxia decreases expression of subunits
of the sodium channel and of the Na,K-ATPase pump [24].
These mechanisms are important in the role of beta-2
agonists in the clearance of alveolar edema.
Effects of beta agonists on alveolar fluid
clearance
Many studies have been carried out to determine the
mechanisms of resolution of alveolar edema in lung injury.
Table 1 highlights numerous experimental studies that
demonstrate the positive role of beta agonists in the
improvement of alveolar edema clearance.
Type II alveolar epithelial cells are mainly responsible for the
mechanism of alveolar edema clearance and are resistant to a
variety of insults. In mild to moderate lung injury, therefore, the
mechanism of active transport of sodium (and water, because
it follows passively) through the epithelium can be up-
regulated. In severe cases of lung injury, where the damage
to the epithelium is extensive, there is often a decrease in
alveolar fluid removal [25].
Beta-2 adrenergic agonists modulate the expression of the
epithelial apical sodium channel as well as the expression of
the Na,K-ATPase pump. Berthiaume and colleagues [25] and
Matthay and colleagues [26] have published relevant reviews
of animal models on resolution of edema in ALI. Pittet and
colleagues [12] demonstrated that endogenous cathecol-
amines stimulate alveolar fluid clearance of a rat model of
septic ALI. When amiloride (which inhibits sodium uptake) and
the beta blocker propranolol were added, the rate of edema
fluid removal decreased. Laffon and colleagues [16] showed
that intravenous lidocaine, a sodium channel inhibitor,
decreased baseline alveolar epithelial fluid clearance by 50%
in rats when albumin solution was instilled into distal air
spaces, and that this effect was reversed by terbutaline. This
strongly suggested the importance of increased transport of
sodium across the alveolar epithelium and of beta adrenergic
receptor stimulation in stimulating alveolar fluid clearance.
Tibayan and colleagues [27] found that dobutamine (a beta-1
and beta-2 agonist) increased alveolar edema clearance but
dopamine (a beta-1 agonist) had no effect on alveolar edema
clearance in anesthetized rats. Consistent with other studies
[28–31], the addition of amiloride reduced the beneficial
effects of dobutamine on edema clearance. Interestingly,
Wang and colleagues [32] found that alveolar edema
clearance was increased by keratinocyte growth factor
because it may have increased proliferation of alveolar type II
cells. Secondary treatment with the beta agonist terbutaline
enhanced the upregulation of fluid transport in these studies,
providing evidence that both treatments increase the ability of
alveolae to clear edema fluid.
Several different beta agonists have been shown to increase
alveolar edema clearance in several different models of ALI.
This suggests that beta agonists could be efficacious in
human ALI caused by many different triggers. Alveolar
epithelial fluid clearance mechanisms are intact after
moderate hyperoxic lung injury in rats [33]. However, Saldias
and colleagues found that the beta agonist isoproterenol
improves clearance of pulmonary edema in hyperoxic rat
lungs [34]. Furthermore, alveolar liquid clearance and arterial
oxygen tension due to hydrostatic pulmonary edema were
increased by aerosolized salmeterol because salmeterol
decreased the left atrial pressure [35].237
The mechanisms that explain the beneficial effect of beta
adrenergic agonists on edema clearance are complex, and
they include cAMP, amiloride-sensitive nonselective cation
channels, and highly selective cation channels. Beta
adrenergic stimulation acts in part by an intracellular cAMP-
dependent mechanism [16,26,36]. Planes and colleagues
[37] showed that terbutaline reverses the hypoxia-induced
decrease in sodium transport by amiloride-sensitive sodium
channel activity because terbutaline activates cAMP and
increases apical expression of the sodium channel subunits.
Terbutaline enhances the insertion of the epithelial sodium
channel subunits into the membrane of hypoxic alveolar
epithelial cells.
Chen and colleagues [38] studied the beta adrenergic
regulation of amiloride-sensitive lung sodium channels and
discovered that beta adrenergic stimulation activates protein
kinase A through the increment of intracellular cAMP. Protein
kinase A increases highly selective cation channel numbers
and the intracellular calcium, which then increases the
nonselective cation channel open probability. Beta adrenergic
stimulation therefore increases both the highly selective
cation channel number and the nonselective cation channel
by increasing cAMP.
There are potentially important differences between short-
term and long-term beta adrenergic stimulation in the lung
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Table 1
Selected studies of alveolar fluid clearance by beta agonists
Study Model Beta-2 agonist Effect
Sartori and colleagues, 2002 [43] High-altitude edema in humans Salmeterol +
Ware and colleagues, 2002 [61] Human donor lung Terbutaline +
Sakuma and colleagues, 1994 [29] Resected human lung Terbutaline +
Atabai and colleagues, 2002 [45] Ventilated patients (ARDS) Albuterol +
Sakuma and colleagues, 1997 [62] Ex vivo human and rat Salmeterol +
Suzuki and colleagues, 1995 [63] Cultured rat alveolar type II Terbutaline +
Minakata and colleagues, 1998 [36] Cultured rat alveolar type II Terbutaline +
Planes and colleagues, 2002 [37] Cultured rat alveolar type II Terbutaline +
Icard and Saumon, 1999 [64] Mice Terbutaline +
Tibayan and colleagues, 1997 [27] Rats Dobutamine +
Barnard and colleagues, 1997 [28] Rats Dopamine +
Charron and colleagues, 1999 [65] Rats Epinephrine +
Saldias and colleagues, 1999 [34] Rats Isoproterenol +
Morgan and colleagues, 2002 [39] Rats Prolonged isoproterenol –
Lasnier and colleagues, 1996 [66] Rats Terbutaline +
Norlin and colleagues, 2001 [31] Rats Terbutaline +
Jayr and colleagues, 1994 [30] Rats Terbutaline +
Saldias and colleagues, 2000 [67] Rats Terbutaline + isoproterenol +
Pittet and colleagues, 1994 [12] Rats Epinephrine +
Rabbit Epinephrine –
Smedira and colleagues, 1991 [68] Rabbit Terbutaline –
Effros and colleagues, 1987 [69] Rabbit Terbutaline –
Campbell and colleagues, 1999 [70] Sheep Salmeterol +
Berthiaume and colleagues, 1987 [71] Sheep Terbutaline +
Berthiaume and colleagues, 1988 [72] Sheep (faster) > dog Terbutaline +
Frank and colleagues, 2000 [35] Sheep and rats Salmeterol +
Grimme and colleagues, 1997 [73] Dogs Terbutaline +
Sugita and colleagues, 2003 [74] Transplanted dogs Terbutaline –
ARDS, acute respiratory distress syndrome; +, increased alveolar edema clearance; –, no effect.238
that are relevant to consideration of beta agonists as therapy
because of desensitization after long-term stimulation. Short-
term (minutes to hours) desensitization does occur and
involves receptor phosphorylation, leading to uncoupling from
the stimulatory G proteins. Short-term desensitization plays a
minor role in alveolar edema clearance. In contrast, long-term
effects (hours to days) cause internalization and degradation
of beta agonist receptors. Long-term stimulation of beta
adrenergic receptors leads to desensitization.
Berthiaume [17] proposed different pathways that increase
sodium transport after acute stimulation (hours) compared
with long-term stimulation (days). Acutely, sodium transport is
enhanced by increased activity of cationic channels and the
Na,K-ATPase pump, by membrane insertion of epithelial
sodium channel subunits, and by changes in chloride
transport. In contrast, after long-term stimulation by beta
agonists, there is increased expression of apical channels
and the Na,K-ATPase pump, and there is stimulation of
epidermal growth factor, leading to increased normal cell
growth that may also enhance edema clearance.
Morgan and colleagues, however, found differences in long-
term administration compared with acute beta agonist
administration [39]: prolonged administration of high doses of
beta agonists reduced the alveolar epithelial response to beta
agonist stimulation. The resolution of alveolar edema
decreased in a dose-dependent manner after 48 hours of
isoproterenol infusion. Morgan and colleagues also showed
that desensitization limits alveolar type II cells’ capacity to
produce cAMP [40]. Desensitization by long-term stimulation
using higher dose beta agonist decreased the adenylate
cyclase function. It would therefore appear that prolonged
beta stimulation in the lung may cause important
desensitization and downregulation of beta adrenergic
receptors in alveolar type II cells, which impairs beta-2
agonist stimulation of fluid removal from lung. This has
relevance to the design of randomized controlled trials of beta
agonists in human ALI.
To summarize, beta-2 adrenergic receptor stimulation
increases sodium, chloride, and fluid absorption by increasing
the activity of the Na,K-ATPase pump and by increasing the
activity of epithelial apical sodium channels in type I and type
II alveolar cells. Beta agonists enhance the clearance of
sodium and of edema fluid in a wide range of animal models
of hydrostatic pulmonary edema and of ALI. There appears to
be beta receptor desensitization to long-term beta adrenergic
stimulation that could influence the design of clinical studies
in human ALI.
Human studies of beta agonists in ALI
There are relatively few studies of the effects of beta-2
adrenergic agents on measures of edema clearance in
humans who have ALI or ARDS. Ware and Matthay [41]
found that the net alveolar fluid clearance was impaired in
56% of patients, particularly in septic patients, who had ALI/
ARDS. Those patients who had maximal alveolar clearance
had better outcomes (more days alive and free of ventilation
and lower mortality) than those who had suboptimal edema
clearance. However, this is evidence of association of edema
clearance and outcome only, and does not prove cause and
effect.
Impairment of the sodium, chloride, and water pathways also
plays a central role in the pathophysiology of high-altitude
pulmonary edema [42,43]. Salmeterol prevented high-altitude
pulmonary edema, and Sartori and colleagues [43]
suggested that the benefit was explained by upregulation of
the alveolar epithelial clearance of alveolar fluid. People
susceptible to high-altitude pulmonary edema may have
genetic differences in the amiloride-sensitive sodium channel
because they have a higher incidence of HLA-DR6 and HLA-
DQ4 antigens [24,42].
Basran and colleagues treated 10 patients who had ARDS
with intravenous terbutaline [44]. Terbutaline inhibited the
increased plasma protein extravasation and accumulation in
the lung, suggesting improved lung vascular permeability.
Atabai and colleagues demonstrated that standard doses of
aerosolized albuterol enhanced clearance of alveolar fluid in
acute pulmonary edema if edema fluid levels of albuterol were
greater than 10–6 M [45]. Indeed, they found that they were
able to achieve therapeutic levels of albuterol in the edema
fluid in human ALI. This is important for two reasons. First, if
inhaled beta-2 agonists are to be effective for edema
clearance in ALI, then there must be therapeutic levels in the
alveolae. Second, there could be impaired delivery of inhaled
beta-2 agonists into the exact alveolae that require treatment —
the flooded alveolae. Atabai’s study is therefore an important
study of the local pharmacokinetics of albuterol in human ALI.
Anti-inflammatory actions of beta agonists in
ALI
ALI is characterized by neutrophil accumulation in the lung, by
production of pro-inflammatory mediators, including
cytokines, by increased activation of cAMP, by disruption of
epithelial integrity, and by interstitial and alveolar edema. Anti-
inflammatory activity of beta agonists may be important in the
resolution of ALI by beta-2 agonists (Table 2).
Beta agonists reduce pulmonary neutrophil sequestration,
reduce pro-inflammatory cytokines (TNF-α, IL-6, IL-8), increase
the anti-inflammatory cytokine IL-10, reduce neutrophil
adhesion to bronchial epithelial and endothelial cells, inhibit
chemotaxis, and reduce oxygen free radical formation.
Dhingra and colleagues [46] found that intravenous beta
adrenergic agonists (dobutamine and dopexamine) attenu-
ated the inflammatory response, particularly the pro-inflam-
matory cytokine expression, the induction of chemokines, and
the infiltration of the lung by neutrophils in a septic rat model
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of ALI. Sekut and colleagues [47] showed that salmeterol
inhibited TNF-α secretion by lipopolysaccharide-activated
THP1 cells, and that this inhibition is reversed by oxprenolol
(a beta-2 antagonist). This cytokine downregulation suggests
an anti-inflammatory property of salmeterol.
Van der Poll and colleagues showed that noradrenaline
decreases TNF-α and IL-6 expression that is increased by
lipopolysaccharide stimulation of macrophages [48].
Epinephrine increased IL-10 and inhibited TNF-α production
[49]. Nakamura and colleagues [50] also found that beta-2
receptor stimulation using terbutaline in cultured rat renal
mesangial cells in the presence of lipopolysaccharide prevented
TNF-α production because of mitogen-activated protein kinase
inhibition and enhanced cAMP generation. The aforementioned
studies suggest an anti-inflammatory effect of beta agonists.
It is interesting, however, to note that the pro-inflammatory
cytokine TNF-α increases fluid clearance. Fukuda and
colleagues [51] found that the combination of TNF-α and
terbutaline did not have an effect on increasing alveolar fluid
clearance in TNF-α-instilled rats. This discovery suggests that
TNF-α-induced fluid transport is not mediated by
endogenous release of beta agonists and probably does not
depend on a cAMP-mediated process. Borjesson and
colleagues [52] found that the increase in alveolar edema
clearance in a model of intestinal ischemia reperfusion was
not mediated by endogenous catecholamine release because
propranolol had no effect and there was no stimulation of
cAMP. The increase in alveolar fluid clearance during
ischemia reperfusion is therefore possibly mediated by
translocation of intestinal bacteria and subsequent activation
of monocytes and macrophages to secrete TNF-α. Arcaroli
and colleagues [53] also noted that alpha adrenergic (but not
beta adrenergic) stimulation modulated the severity of ALI
after hemorrhage and endotoxemia.
Beta adrenergic agents also act on neutrophils to modulate
ALI. Salbutamol decreases neutrophil chemotaxis, but not
activation of neutrophils or adhesion molecule expression [54].
In summary, beta agonists exhibit anti-inflammatory properties
that may be relevant in the severity and progression of ALI/
ARDS. However, the role of increased fluid clearance with
inflammatory cytokines such as TNF-α remains to be
determined.
Bronchodilator effects of beta-2 agonists in ALI
Beta agonists decrease respiratory system resistance [55–57]
and increase both the dynamic compliance and the static
compliance of patients with ARDS [56] (Table 3).
The increase of dynamic compliance is consistent with
bronchodilator effects of salbutamol. The increase in static
compliance is intriguing because it suggests other
nonbronchodilator effects of salbutamol in these patients,
such as changes in the quantity of tissue edema. It has been
shown that both nebulized salbutamol (1 mg through an
Available online http://ccforum.com/content/8/4/234
Table 2
Selected studies of anti-inflammatory effects of beta agonists in acute lung injury
Study Model Treatment Effect
Perkins and colleagues, 2003 [54] Human neutrophils Salbutamol Inhibited chemotaxis
Sekut and colleagues, 1995 [47] Lipopolysaccharide- Salmeterol, salbutamol Inhibited TNF-α
activated THP1 cells
Dhingra and colleagues, 2001 [46] Murine sepsis Dobutamine, dopexamine Attenuated inflammatory cytokine 
expression and chemokines induction
Van der Poll and colleagues, 1994 [48] Lipopolysaccharide- Norepinephrine Decreased TNF-α, IL-6
stimulated macrophages
Van der Poll and Lowry, 1997 [49] Human endotoxemia Epinephrine Increased IL-10
TNF-α, tumor necrosis factor alpha.
Table 3
Selected studies of bronchodilator effects of beta agonists in acute lung injury
Study Cohort Treatment Effect
Morina and colleagues, 1997 [56] Human ARDS Salbutamol Decreased airway resistance, increased compliance
Pesenti and colleagues, 1993 [55] Human ARDS Salbutamol Decreased airway resistance
Wright and colleagues, 1994 [57] Human ARDS Metoproterenol Decreased airway resistance
ARDS, acute respiratory distress syndrome.240
endotracheal tube) [56] and continuous intravenous infusion
(15 µg/min for at least 30 min) [55] decrease respiratory
system resistance and the abnormal high airway pressure of
ARDS patients, and may attenuate the risk of barotraumas.
Wright and colleagues [57] also showed that endotracheal
metoproterenol (5 mg) decreased high airway resistance of
ARDS patients with a tendency to improve oxygenation.
Effects of beta-2 agonists on surfactant
Surfactant deficiency plays an important secondary role in the
pathogenesis of ALI by altering alveolar surface tension and by
altering antibacterial defenses of the lung. Surfactant
deficiency may be important in the propagation of adult ALI.
Beta agonists have some favorable effects on surfactant in ALI.
von Wichert and colleagues [58] studied the effect of
fenoterol on the lung phospholipid metabolism in septic rats.
Fenoterol increased the incorporation of choline by 80% in
normal lungs and by 35% in septic lungs. Fenoterol restored
phosphatidylcholine to normal in bronchoalveolar lavage fluid
and in lung tissue.
Polack and colleagues [59] showed that prolonged exposure
to hyperoxia decreases surfactant synthesis and that beta
adrenergic stimulation enhances the release of newly
synthesized surfactant into the alveoli in neonatal lungs. The
beta agonists terbutaline and salmeterol increased phospha-
tidylcholine secretion by adult and fetal type II cells [60] in a
dose-dependent manner.
Summary
Many experimental studies of the physiopathology of alveolar
edema in ALI indicate that cellular mechanisms are important
in the resolution of ALI. Several of these mechanisms are
amenable to improvement by beta-2 agonists. Specifically,
beta-2 antagonists increase sodium transport, and thus
edema clearance, they are anti-inflammatory, and they induce
bronchodilation. The preclinical studies of the effects of beta-2
adrenergic agonists in models of ALI/ARDS open an exciting
horizon of therapeutic implications. A limited number of
studies of beta agonists in human ALI show that respiratory
mechanics are improved, that therapeutic levels of albuterol
can be achieved in the edema fluid, and that edema fluid
clearance is increased. This challenges investigators to study
the safety and efficacy of beta-2 agonists for the treatment of
human ALI/ARDS. This strategy may be particularly
advantageous because beta-2 agonists may be relatively
safe, inexpensive, and easy to administer in this setting. Well-
designed, randomized controlled trials of beta agonists for
ALI/ARDS are now warranted.
Competing interests
None declared.
Acknowledgement
KRW is a Michael Smith Foundation for Health Research Distinguished
Scholar.
References
1. Ashbaugh DG, Bigelow DB, Petty TL, Levine BE: Acute
respiratory distress in adults. Lancet 1967, 2:319-323.
2. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L,
Lamy M, Legall JR, Morris A, Spragg R: The American–European
Consensus Conference on ARDS. Definitions, mechanisms,
relevant outcomes, and clinical trial coordination. Am J Respir
Crit Care Med 1994, 149:818-824.
3. ARDS Network: Ventilation with lower tidal volumes as
compared with traditional tidal volumes for acute lung injury
and the acute respiratory distress syndrome. The Acute
Respiratory Distress Syndrome Network. N Engl J Med 2000,
342:1301-1308.
4. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF,
Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely
EW, Fisher CJ Jr: Efficacy and safety of recombinant human
activated protein C for severe sepsis. N Engl J Med 2001, 344:
699-709.
5. Dhingra V, Russell JA, Walley KR: Overview, Clinical Evaluation,
and Chest Radiology of ARDS. In Acute Respiratory Distress
Syndrome — A comprehensive approach. Russell JA, Walley KR
(eds). London: Cambridge University Press; 1999:6-28.
6. Matthay MA, Zimmerman GA, Esmon C, Bhattacharya J, Coller B,
Doerschuk CM, Floros J, Gimbrone MA Jr, Hoffman E, Hubmayr
RD, Leppert M, Matalon S, Munford R, Parsons P, Slutsky AS,
Tracey KJ, Ward P, Gail DB, Harabin AL: Future research
directions in acute lung injury: summary of a National Heart,
Lung, and Blood Institute working group. Am J Respir Crit
Care Med 2003, 167:1027-1035.
7. Ware LB, Matthay MA: The acute respiratory distress
syndrome. N Engl J Med 2000, 342:1334-1349.
8. Pugin J, Verghese G, Widmer MC, Matthay MA: The alveolar
space is the site of intense inflammatory and profibrotic
reactions in the early phase of acute respiratory distress
syndrome. Crit Care Med 1999, 27:304-312.
9. Johnson MD, Widdicombe JH, Allen L, Barbry P, Dobbs LG:
Alveolar epithelial type I cells contain transport proteins and
transport sodium, supporting an active role for type I cells in
regulation of lung liquid homeostasis. Proc Natl Acad Sci USA
2002, 99:1966-1971.
10. Ridge KM, Olivera WG, Saldias F, Azzam Z, Horowitz S,
Rutschman DH, Dumasius V, Factor P, Sznajder JI: Alveolar type
1 cells express the alpha2 Na,K-ATPase, which contributes to
lung liquid clearance. Circ Res 2003, 92:453-460.
11. Borok Z, Liebler JM, Lubman RL, Foster MJ, Zhou B, Li X, Zabski
SM, Kim KJ, Crandall ED: Na transport proteins are expressed
by rat alveolar epithelial type I cells. Am J Physiol Lung Cell
Mol Physiol 2002, 282:L599-L608.
12. Pittet JF, Wiener-Kronish JP, McElroy MC, Folkesson HG, Matthay
MA:  Stimulation of lung epithelial liquid clearance by
endogenous release of catecholamines in septic shock in
anesthetized rats. J Clin Invest 1994, 94:663-671.
13. Matthay MA, Fukuda N, Frank J, Kallet R, Daniel B, Sakuma T:
Alveolar epithelial barrier. Role in lung fluid balance in clinical
lung injury. Clin Chest Med 2000, 21:477-490.
14. Sartori C, Matthay MA, Scherrer U: Transepithelial sodium and
water transport in the lung. Major player and novel therapeutic
target in pulmonary edema. Adv Exp Med Biol 2001, 502:315-
338.
15. Sartori C, Matthay MA: Alveolar epithelial fluid transport in
acute lung injury: new insights. Eur Respir J 2002, 20:1299-
1313.
16. Laffon M, Jayr C, Barbry P, Wang Y, Folkesson HG, Pittet JF,
Clerici C, Matthay MA: Lidocaine induces a reversible decrease
in alveolar epithelial fluid clearance in rats. Anesthesiology
2002, 96:392-399.
17. Berthiaume Y: Long-term stimulation of alveolar epithelial cells
by beta-adrenergic agonists: increased Na+ transport and
modulation of cell growth? Am J Physiol Lung Cell Mol Physiol
2003, 285:L798-L801.
18. Reddy MM, Light MJ, Quinton PM: Activation of the epithelial
Na+ channel (ENaC) requires CFTR Cl– channel function.
Nature 1999, 402:301-304.
19. Jiang X, Ingbar DH, O’Grady SM: Adrenergic stimulation of Na+
transport across alveolar epithelial cells involves activation of
apical Cl– channels. Am J Physiol 1998, 275:C1610-C1620.
Critical Care    August 2004 Vol 8 No 4 Groshaus et al.241
Available online http://ccforum.com/content/8/4/234
20. O’Grady SM, Lee SY: Chloride and potassium channel
function in alveolar epithelial cells. Am J Physiol Lung Cell Mol
Physiol 2003, 284:L689-L700.
21. O’Grady SM, Jiang X, Ingbar DH: Cl– channel activation is
necessary for stimulation of Na transport in adult alveolar
epithelial cells. Am J Physiol Lung Cell Mol Physiol 2000, 278:
L239-L244.
22. Matthay MA, Folkesson HG, Verkman AS: Salt and water
transport across alveolar and distal airway epithelia in the
adult lung. Am J Physiol 1996, 270:L487-L503.
23. Borok Z, Verkman AS: Lung edema clearance: 20 years of
progress: invited review: role of aquaporin water channels in
fluid transport in lung and airways. J Appl Physiol 2002,
93:2199-2206.
24. Voelkel NF: High-altitude pulmonary edema. N Engl J Med
2002, 346:1606-1607.
25. Berthiaume Y, Folkesson HG, Matthay MA: Lung edema
clearance: 20 years of progress: invited review: alveolar
edema fluid clearance in the injured lung. J Appl Physiol 2002,
93:2207-2213.
26. Matthay MA, Clerici C, Saumon G: Invited review: active fluid
clearance from the distal air spaces of the lung. J Appl Physiol
2002, 93:1533-1541.
27. Tibayan FA, Chesnutt AN, Folkesson HG, Eandi J, Matthay MA:
Dobutamine increases alveolar liquid clearance in ventilated
rats by beta-2 receptor stimulation. Am J Respir Crit Care Med
1997, 156:438-444.
28. Barnard ML, Olivera WG, Rutschman DM, Bertorello AM, Katz AI,
Sznajder JI: Dopamine stimulates sodium transport and liquid
clearance in rat lung epithelium. Am J Respir Crit Care Med
1997, 156:709-714.
29. Sakuma T, Okaniwa G, Nakada T, Nishimura T, Fujimura S,
Matthay MA: Alveolar fluid clearance in the resected human
lung. Am J Respir Crit Care Med 1994, 150:305-310.
30. Jayr C, Garat C, Meignan M, Pittet JF, Zelter M, Matthay MA:
Alveolar liquid and protein clearance in anesthetized
ventilated rats. J Appl Physiol 1994, 76:2636-2642.
31. Norlin A, Lu LN, Guggino SE, Matthay MA, Folkesson HG:
Contribution of amiloride-insensitive pathways to alveolar
fluid clearance in adult rats. J Appl Physiol 2001,  90:1489-
1496.
32. Wang Y, Folkesson HG, Jayr C, Ware LB, Matthay MA: Alveolar
epithelial fluid transport can be simultaneously upregulated
by both KGF and beta-agonist therapy. J Appl Physiol 1999,
87:1852-1860.
33. Garat C, Meignan M, Matthay MA, Luo DF, Jayr C: Alveolar
epithelial fluid clearance mechanisms are intact after
moderate hyperoxic lung injury in rats. Chest 1997, 111:1381-
1388.
34. Saldias FJ, Comellas A, Ridge KM, Lecuona E, Sznajder JI:
Isoproterenol improves ability of lung to clear edema in rats
exposed to hyperoxia. J Appl Physiol 1999, 87:30-35.
35. Frank JA, Wang Y, Osorio O, Matthay MA: Beta-adrenergic
agonist therapy accelerates the resolution of hydrostatic
pulmonary edema in sheep and rats. J Appl Physiol 2000, 89:
1255-1265.
36. Minakata Y, Suzuki S, Grygorczyk C, Dagenais A, Berthiaume Y:
Impact of beta-adrenergic agonist on Na+ channel and Na+-
K+-ATPase expression in alveolar type II cells. Am J Physiol
1998, 275:L414-L422.
37. Planes C, Blot-Chabaud M, Matthay MA, Couette S, Uchida T,
Clerici C: Hypoxia and beta 2-agonists regulate cell surface
expression of the epithelial sodium channel in native alveolar
epithelial cells. J Biol Chem 2002, 277:47318-47324.
38. Chen XJ, Eaton DC, Jain L: Beta-adrenergic regulation of
amiloride-sensitive lung sodium channels. Am J Physiol Lung
Cell Mol Physiol 2002, 282:L609-L620.
39. Morgan EE, Hodnichak CM, Stader SM, Maender KC, Boja JW,
Folkesson HG, Maron MB: Prolonged isoproterenol infusion
impairs the ability of beta(2)-agonists to increase alveolar
liquid clearance. Am J Physiol Lung Cell Mol Physiol 2002, 282:
L666-L674.
40. Morgan EE, Stader SM, Hodnichak CM, Mavrich KE, Folkesson
HG, Maron MB: Postreceptor defects in alveolar epithelial
beta-adrenergic signaling after prolonged isoproterenol
infusion. Am J Physiol Lung Cell Mol Physiol 2003, 285:L578-
L583.
41. Ware LB, Matthay MA: Alveolar fluid clearance is impaired in
the majority of patients with acute lung injury and the acute
respiratory distress syndrome. Am J Respir Crit Care Med
2001, 163:1376-1383.
42. Hackett PH, Roach RC: High-altitude illness. N Engl J Med
2001, 345:107-114.
43. Sartori C, Allemann Y, Duplain H, Lepori M, Egli M, Lipp E, Hutter
D, Turini P, Hugli O, Cook S, Nicod P, Scherrer U: Salmeterol for
the prevention of high-altitude pulmonary edema. N Engl J
Med 2002, 346:1631-1636.
44. Basran GS, Hardy JG, Woo SP, Ramasubramanian R, Byrne AJ:
Beta-2-adrenoceptor agonists as inhibitors of lung vascular
permeability to radiolabelled transferrin in the adult
respiratory distress syndrome in man. Eur J Nucl Med 1986,
12:381-384.
45. Atabai K, Ware LB, Snider ME, Koch P, Daniel B, Nuckton TJ,
Matthay MA: Aerosolized beta(2)-adrenergic agonists achieve
therapeutic levels in the pulmonary edema fluid of ventilated
patients with acute respiratory failure. Intensive Care Med
2002, 28:705-711.
46. Dhingra VK, Uusaro A, Holmes CL, Walley KR: Attenuation of
lung inflammation by adrenergic agonists in murine acute
lung injury. Anesthesiology 2001, 95:947-953.
47. Sekut L, Champion BR, Page K, Menius JA, Jr, Connolly KM: Anti-
inflammatory activity of salmeterol: down-regulation of
cytokine production. Clin Exp Immunol 1995, 99:461-466.
48. Van der Poll T, Jansen J, Endert E, Sauerwein HP, van Deventer
SJ: Noradrenaline inhibits lipopolysaccharide-induced tumor
necrosis factor and interleukin 6 production in human whole
blood. Infect Immun 1994, 62:2046-2050.
49. Van der Poll T, Lowry SF: Epinephrine inhibits endotoxin-
induced IL-1 beta production: roles of tumor necrosis factor-
alpha and IL-10. Am J Physiol 1997, 273:R1885-R1890.
50. Nakamura A, Imaizumi A, Kohsaka T, Yanagawa Y, Johns EJ:
Beta2-adrenoceptor agonist suppresses tumour necrosis
factor production in rat mesangial cells. Cytokine  2000, 12:
491-494.
51. Fukuda N, Jayr C, Lazrak A, Wang Y, Lucas R, Matalon S, Matthay
MA:  Mechanisms of TNF-alpha stimulation of amiloride-
sensitive sodium transport across alveolar epithelium. Am J
Physiol Lung Cell Mol Physiol 2001, 280:L1258-L1265.
52. Borjesson A, Norlin A, Wang X, Andersson R, Folkesson HG:
TNF-alpha stimulates alveolar liquid clearance during
intestinal ischemia-reperfusion in rats. Am J Physiol Lung Cell
Mol Physiol 2000, 278:L3-L12.
53. Arcaroli J, Yang KY, Yum HK, Kupfner J, Pitts TM, Park JS,
Strassheim D, Abraham E: Effects of catecholamines on kinase
activation in lung neutrophils after hemorrhage or
endotoxemia. J Leukoc Biol 2002, 72:571-579.
54. Perkins GD QS, Thickett DR, Gao F: The effects of salbutamol on
neutrophil function [abstract]. Crit Care 2003, 7(Suppl 2):P035.
55. Pesenti A, Pelosi P, Rossi N, Aprigliano M, Brazzi L, Fumagalli R:
Respiratory mechanics and bronchodilator responsiveness in
patients with the adult respiratory distress syndrome. Crit
Care Med 1993, 21:78-83.
56. Morina P, Herrera M, Venegas J, Mora D, Rodriguez M, Pino E:
Effects of nebulized salbutamol on respiratory mechanics in
adult respiratory distress syndrome. Intensive Care Med 1997,
23:58-64.
57. Wright PE, Carmichael LC, Bernard GR: Effect of
bronchodilators on lung mechanics in the acute respiratory
distress syndrome (ARDS). Chest 1994, 106:1517-1523.
58. von Wichert P, Muller B, Meyer-Ingold W: Influence of a beta-
adrenergic agonist on septic shock-induced alterations of
phosphatidylcholine metabolism in rat lung. Lung 1988, 166:
257-267.
59. Polak MJ, Knight ME, Andresen TL, DeSena C: Effects of
hyperoxia and beta-adrenergic stimulation on pulmonary
surfactant in neonatal rabbits. Exp Lung Res 1992,  18:373-
384.
60. Kumar VH, Christian C, Kresch MJ: Effects of salmeterol on
secretion of phosphatidylcholine by alveolar type II cells. Life
Sci 2000, 66:1639-1646.
61. Ware LB, Fang X, Wang Y, Sakuma T, Hall TS, Matthay MA:
Selected contribution: mechanisms that may stimulate the
resolution of alveolar edema in the transplanted human lung.
J Appl Physiol 2002, 93:1869-1874.242
Critical Care    August 2004 Vol 8 No 4 Groshaus et al.
62. Sakuma T, Folkesson HG, Suzuki S, Okaniwa G, Fujimura S,
Matthay MA: Beta-adrenergic agonist stimulated alveolar fluid
clearance in ex vivo human and rat lungs. Am J Respir Crit
Care Med 1997, 155:506-512.
63. Suzuki S, Zuege D, Berthiaume Y: Sodium-independent
modulation of Na(+)-K(+)-ATPase activity by beta-adrenergic
agonist in alveolar type II cells. Am J Physiol 1995, 268:L983-
L990.
64. Icard P, Saumon G: Alveolar sodium and liquid transport in
mice. Am J Physiol 1999, 277:L1232-L1238.
65. Charron PD, Fawley JP, Maron MB: Effect of epinephrine on
alveolar liquid clearance in the rat. J Appl Physiol 1999, 87:
611-618.
66. Lasnier JM, Wangensteen OD, Schmitz LS, Gross CR, Ingbar
DH:  Terbutaline stimulates alveolar fluid resorption in
hyperoxic lung injury. J Appl Physiol 1996, 81:1723-1729.
67. Saldias FJ, Lecuona E, Comellas AP, Ridge KM, Rutschman DH,
Sznajder JI: Beta-adrenergic stimulation restores rat lung
ability to clear edema in ventilator-associated lung injury. Am
J Respir Crit Care Med 2000, 162:282-287.
68. Smedira N, Gates L, Hastings R, Jayr C, Sakuma T, Pittet JF,
Matthay MA: Alveolar and lung liquid clearance in anesthetized
rabbits. J Appl Physiol 1991, 70:1827-1835.
69. Effros RM, Mason GR, Hukkanen J, Silverman P: Reabsorption of
solutes and water from fluid-filled rabbit lungs. Am Rev Respir
Dis 1987, 136:669-676.
70. Campbell AR, Folkesson HG, Berthiaume Y, Gutkowska J, Suzuki
S, Matthay MA: Alveolar epithelial fluid clearance persists in
the presence of moderate left atrial hypertension in sheep.
J Appl Physiol 1999, 86:139-151.
71. Berthiaume Y, Staub NC, Matthay MA: Beta-adrenergic
agonists increase lung liquid clearance in anesthetized
sheep. J Clin Invest 1987, 79:335-343.
72. Berthiaume Y, Broaddus VC, Gropper MA, Tanita T, Matthay MA:
Alveolar liquid and protein clearance from normal dog lungs.
J Appl Physiol 1988, 65:585-593.
73. Grimme JD, Lane SM, Maron MB: Alveolar liquid clearance in
multiple nonperfused canine lung lobes. J Appl Physiol 1997,
82:348-353.
74. Sugita M, Ferraro P, Dagenais A, Clermont ME, Barbry P, Michel
RP, Berthiaume Y: Alveolar liquid clearance and sodium
channel expression are decreased in transplanted canine
lungs. Am J Respir Crit Care Med 2003, 167:1440-1450.